A detailed history of Entry Point Capital, LLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 6,152 shares of YMAB stock, worth $96,524. This represents 0.11% of its overall portfolio holdings.

Number of Shares
6,152
Holding current value
$96,524
% of portfolio
0.11%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$11.6 - $17.25 $71,363 - $106,122
6,152 New
6,152 $74.3 Million
Q4 2023

Feb 14, 2024

BUY
$4.88 - $7.42 $204,711 - $311,261
41,949 New
41,949 $286 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $686M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.